The More Things Change: Gene Therapy Reopens Orphan Drug 'Sameness' Debate
You may also be interested in...
US FDA draft guidance says that ‘minor differences’ in transgenes and/or vectors won’t be enough for orphan exclusivity, but agency will consider ‘additional features of the final product’ in making the determination.
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.